De Guzman, Keonna O.
HRN: 22-77-92 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/27/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/27/2023
04/03/2023
IV
40mg
Q24h
Potentially Septic Newborn (Thickly Msaf)
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes